bluebird bio (BLUE) Receives Media Sentiment Rating of 0.19
News coverage about bluebird bio (NASDAQ:BLUE) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. bluebird bio earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.6567945204499 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- bluebird bio, Inc. (BLUE) Earns “Buy” Rating from Goldman Sachs Group, Inc. (The) (americanbankingnews.com)
- Leerink Swann Reaffirms Outperform Rating for bluebird bio, Inc. (BLUE) (americanbankingnews.com)
- Gene therapy may be breakthrough for boys with ‘Lorenzo’s Oil’ disease (upi.com)
- bluebird bio to Present at Chardan Gene Therapy Conference (finance.yahoo.com)
Shares of bluebird bio (NASDAQ:BLUE) opened at 127.75 on Friday. bluebird bio has a 1-year low of $37.05 and a 1-year high of $143.50. The firm has a 50-day moving average price of $121.47 and a 200-day moving average price of $100.75. The company’s market capitalization is $5.82 billion.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. During the same quarter last year, the company earned ($1.59) earnings per share. The business’s revenue was up 977.4% on a year-over-year basis. Equities analysts anticipate that bluebird bio will post ($6.85) earnings per share for the current year.
Several research analysts recently commented on the stock. Cantor Fitzgerald restated a “sell” rating and issued a $39.00 price target on shares of bluebird bio in a report on Thursday, September 28th. Leerink Swann restated an “outperform” rating and issued a $120.00 price target on shares of bluebird bio in a report on Saturday, September 30th. Morgan Stanley lowered shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 price target on the stock. in a report on Monday, October 2nd. Wells Fargo & Company restated an “outperform” rating and issued a $158.00 price target (up previously from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Finally, Barclays PLC assumed coverage on shares of bluebird bio in a report on Wednesday, September 6th. They issued an “overweight” rating and a $151.00 price target on the stock. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $113.41.
ILLEGAL ACTIVITY WARNING: “bluebird bio (BLUE) Receives Media Sentiment Rating of 0.19” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/bluebird-bio-blue-receives-media-sentiment-rating-of-0-19/1616849.html.
In other news, insider David Davidson sold 3,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $92.37, for a total transaction of $277,110.00. Following the sale, the insider now owns 18,977 shares in the company, valued at $1,752,905.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeffrey T. Walsh sold 2,500 shares of the stock in a transaction on Monday, July 10th. The stock was sold at an average price of $99.89, for a total value of $249,725.00. Following the sale, the insider now owns 29,805 shares in the company, valued at approximately $2,977,221.45. The disclosure for this sale can be found here. Insiders have sold 129,379 shares of company stock worth $15,651,533 in the last 90 days. Company insiders own 3.90% of the company’s stock.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.